GB202303387D0 - Compounds - Google Patents
CompoundsInfo
- Publication number
- GB202303387D0 GB202303387D0 GBGB2303387.1A GB202303387A GB202303387D0 GB 202303387 D0 GB202303387 D0 GB 202303387D0 GB 202303387 A GB202303387 A GB 202303387A GB 202303387 D0 GB202303387 D0 GB 202303387D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2303387.1A GB202303387D0 (en) | 2023-03-08 | 2023-03-08 | Compounds |
| PCT/GB2024/050610 WO2024184650A1 (en) | 2023-03-08 | 2024-03-07 | Bicyclic heteroaryl compounds for use as gpr35 modulators. |
| KR1020257033461A KR20250166190A (en) | 2023-03-08 | 2024-03-07 | Bicyclic heteroaryl compounds for use as GPR35 modulators |
| AU2024232876A AU2024232876A1 (en) | 2023-03-08 | 2024-03-07 | Bicyclic heteroaryl compounds for use as gpr35 modulators. |
| CN202480030080.7A CN121039128A (en) | 2023-03-08 | 2024-03-07 | Bicyclic heteroaryl compounds used as GPR35 modifiers |
| MX2025010498A MX2025010498A (en) | 2023-03-08 | 2025-09-05 | Bicyclic heteroaryl compounds for use as gpr35 modulators. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2303387.1A GB202303387D0 (en) | 2023-03-08 | 2023-03-08 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202303387D0 true GB202303387D0 (en) | 2023-04-19 |
Family
ID=85980348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2303387.1A Ceased GB202303387D0 (en) | 2023-03-08 | 2023-03-08 | Compounds |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20250166190A (en) |
| CN (1) | CN121039128A (en) |
| AU (1) | AU2024232876A1 (en) |
| GB (1) | GB202303387D0 (en) |
| MX (1) | MX2025010498A (en) |
| WO (1) | WO2024184650A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005119252A2 (en) | 2004-05-26 | 2005-12-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr35 for the treatment of metabolic-related disorders |
| US20100197688A1 (en) * | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| TWI845600B (en) * | 2019-01-24 | 2024-06-21 | 美商普羅米修斯生物科學股份有限公司 | Gpr35 modulators |
| JP7386576B2 (en) * | 2019-10-02 | 2023-11-27 | カイノス・メディスン・インコーポレイテッド | N-(1H-imidazol-2-yl)benzamide compounds and pharmaceutical compositions containing the compounds as active ingredients |
| EP4334301A1 (en) * | 2021-05-05 | 2024-03-13 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
-
2023
- 2023-03-08 GB GBGB2303387.1A patent/GB202303387D0/en not_active Ceased
-
2024
- 2024-03-07 KR KR1020257033461A patent/KR20250166190A/en active Pending
- 2024-03-07 WO PCT/GB2024/050610 patent/WO2024184650A1/en active Pending
- 2024-03-07 AU AU2024232876A patent/AU2024232876A1/en active Pending
- 2024-03-07 CN CN202480030080.7A patent/CN121039128A/en active Pending
-
2025
- 2025-09-05 MX MX2025010498A patent/MX2025010498A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024184650A1 (en) | 2024-09-12 |
| MX2025010498A (en) | 2025-12-01 |
| CN121039128A (en) | 2025-11-28 |
| KR20250166190A (en) | 2025-11-27 |
| AU2024232876A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202200735D0 (en) | Compounds | |
| GB202208643D0 (en) | Compounds | |
| GB202300021D0 (en) | Compounds | |
| GB202214796D0 (en) | Compounds | |
| GB202208151D0 (en) | Compounds | |
| GB202201996D0 (en) | Compounds | |
| CA3257510A1 (en) | Compounds | |
| GB202303387D0 (en) | Compounds | |
| GB202303419D0 (en) | Compounds | |
| GB202303230D0 (en) | Compounds | |
| GB202302871D0 (en) | Compounds | |
| GB202302237D0 (en) | Tryptophan-based compounds | |
| GB202302032D0 (en) | Compounds | |
| GB202300995D0 (en) | Compounds | |
| GB202301012D0 (en) | Compounds | |
| GB202301024D0 (en) | Compounds | |
| GB202301008D0 (en) | Compounds | |
| GB202301000D0 (en) | Compounds | |
| GB202300922D0 (en) | Compounds | |
| GB202219706D0 (en) | Compounds | |
| GB202219534D0 (en) | Compounds | |
| GB202217844D0 (en) | Compounds | |
| GB202217330D0 (en) | Compounds | |
| GB202216695D0 (en) | Compounds | |
| GB202215664D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |